CompletedPhase 2

Treatment of Patients With Blepharitis and Facial Rosacea

United States70 participantsStarted 2007-11

Plain-language summary

To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * blepharitis * facial rosacea Exclusion Criteria: * pregnant or nursing women * allergy to tetracyclines * recent eye surgery * past or current use of isotretinoin * patients who are achlorhydric * patients who have had gastric by-pass surgery

What they're measuring

Change in Bulbar Conjunctival Hyperemia

Timeframe: Baseline to Week 12

Change in Ocular Surface Disease Index (OSDI)

Timeframe: Baseline to Week 12

Trial details

NCT IDNCT00560703

SponsorGalderma R&D

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-05

Results submitted2011-04-28

View on ClinicalTrials.gov More Blepharitis trials